Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies

Journal of Child Neurology

Volumn 24, Issue 12, 2009, Pages 1520-1525

  Wheless, James W ^a   Conry, Joan ^b   Krauss, Gregory ^c   Mann, Allison ^c   Lopresti, Antonia ^d   Narurkar, Milind ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EISAI INC   (United States)

Author keywords

Epilepsy; Lennox Gastaut syndrome; Rufinamide; Safety; Seizures

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; APPENDICITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHICKENPOX; CHILD; CLINICAL TRIAL; DECREASED APPETITE; DEHYDRATION; DIASTOLIC BLOOD PRESSURE; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GASTRITIS; HUMAN; HYPOTHYROIDISM; IRRITABILITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LENNOX GASTAUT SYNDROME; LETHARGY; LEUKOPENIA; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SKIN ALLERGY; SOMNOLENCE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TONIC CLONIC SEIZURE; TOXIC HEPATITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; DRUG TOXICITY; EPILEPSY; FEMALE; HEADACHE; HUMANS; MALE; TREATMENT OUTCOME; TRIAZOLES; VOMITING;

EID: 75149122341     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073809350508     Document Type: Article

References (9)

1. Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008 ; 49 (7). 1123-1141.
2. Glauser T., Kluger G., Sachdeo R., Krauss G., Perdomo C., Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 ; 70 (21). 1950-1958.
3. Brodie MJ, Rosenfeld WE, Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009 ; 50 (8). 1899-1909.
4. Hwang H., Kim KJ New antiepileptic drugs in pediatric epilepsy. Brain Dev. 2008 ; 30 (9). 549-555.
5. Topamax [prescribing information]. Titusville, NJ: Ortho-McNeil Neurologics ; 2008. http://www.topamaxepilepsy.com/topamaxepilepsy/prescribing- info.html. Accessed October 12, 2009.
6. Lamictal [prescribing information]. Research Triangle Park, NC: Glaxo Smithkline ; 2009. http://us.gsk.com/products/assets/us-lamictal.pdf. Accessed October 12, 2009.
7. Kluger G., Kurlemann G., Haberlandt E., et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy first European experience. Epilepsy Behav. 2009 ; 14 (3). 491-495.
8. Knowles SR, Shapiro LE, Shear NH Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999 ; 21 (6). 489-501.
9. Aldenkamp AP Antiepileptic drug treatment and epileptic seizures: effects on cognitive function. In: Trimble M, Schmitz B, eds. The Neuropsychiatry of Epilepsy. New York, NY: Cambridge University Press; 2002: 256-267.